Background: Δ-Tetrahydrocannabinol (THC) is already considered one of the most addictive substances since an increasing number of consumers/abusers of THC and THC based products are observed worldwide. In this work, the capabilities of a novel miniaturized and portable MicroNIR spectrometer were investigated in order to propose a practical and intelligible test allowing the rapid and easy screening of Δ-Tetrahydrocannabinol (THC) oral fluids without any pretreatment.

Methods: Specimens from volunteers were collected in order to consider any sources of variability in the spectral response and spiked with increasing amount of THC in order to realize predictive models to be used in real cases. Partial Least Square-Discriminant Analysis (PLS-DA) and Partial Least Square regression (PLSr) for the simultaneously detection and quantification of THC, were applied to baseline corrected spectra pre-treated by first derivative transform.

Results: Results demonstrated that MicroNIR/Chemometric platform is statistically able to identify THC abuse in simulated oral fluid samples containing THC from 10 to 100 ng/ml, with a precision and a sensitivity of about 1.51% and 0.1% respectively.

Conclusions: The coupling MicroNIR/Chemometrics permits to simplify THC abuse monitoring for roadside drug testing or workplace surveillance and provides the rapid interpretation of results, as once the model is assessed, it can be used to process real samples in a "click-on" device.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2019.107578DOI Listing

Publication Analysis

Top Keywords

thc
10
thc oral
8
oral fluids
8
Δ-tetrahydrocannabinol thc
8
thc abuse
8
micronir/chemometrics analytical
4
analytical platform
4
platform fast
4
fast accurate
4
accurate detection
4

Similar Publications

Cannabinoid receptor 1 (CB1R) has been extensively studied as a potential therapeutic target for various conditions, including pain management, obesity, emesis, and metabolic syndrome. Unlike orthosteric agonists such as Δ-tetrahydrocannabinol (THC), cannabidiol (CBD) has been identified as a negative allosteric modulator (NAM) of CB1R, among its other pharmacological targets. Previous computational and structural studies have proposed various binding sites for CB1R NAMs.

View Article and Find Full Text PDF

Aims: To establish the feasibility of using ecological momentary assessment (EMA) to estimate total quantities of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) used across different forms of cannabis, and to assess the predictive validity of THC estimates for predicting acute cannabis-related consequences.

Design: 14-day EMA using a smartphone application to assess cannabis use in real time.

Setting: Canada.

View Article and Find Full Text PDF

Marijuana poisoning in canines is still considered a taboo topic. Poisoning in pets is becoming increasingly common, in many cases resulting in severe clinical signs, such as ataxia, urinary incontinence, mydriasis, depression, and hyperesthesia. Colombia does not have any reliable test for the diagnosis of exposure to cannabis in animals, and it is not an obligation to report this kind of poisoning to the authorities.

View Article and Find Full Text PDF

Cannabidiol (CBD) and Δ-tetrahydrocannabinol (THC), the main components of Cannabis sativa plants, can interact with specific cell receptors known as cannabinoid receptors (CBs). The endogenous compounds anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are CB agonists, and, alongside enzymes, they constitute the endocannabinoid system (ECS) and take part in neuromodulation. Several LC-MS/MS methods have been developed to quantify these compounds in biological matrixes, but a fast and simple method that can determine these analytes in plasma samples simultaneously is not available.

View Article and Find Full Text PDF

Chronic obstructive pulmonary disease (COPD) is a common condition that complicates major surgeries like coronary artery bypass grafting (CABG). This study aims to evaluate the impact of COPD on the outcome of CABG. A registry-based retrospective cohort study included individuals who received CABG between 2009 and 2016.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!